Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 11c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.61), $0.11 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $57.4 million versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
• Kraken Robotics closes $615M Covelya acquisition, raises 2026 outlook
• Elevance (ELV) PT Raised to $482 at Bernstein SocGen